Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
4.56M
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
126M
-
Shares change
-
+2.47M
-
Total reported value, excl. options
-
$841M
-
Value change
-
+$15M
-
Put/Call ratio
-
0.85
-
Number of buys
-
82
-
Number of sells
-
-44
-
Price
-
$6.67
Significant Holders of RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) as of Q1 2023
173 filings reported holding RXRX - RECURSION PHARMACEUTICALS, INC. - Common Stock as of Q1 2023.
RECURSION PHARMACEUTICALS, INC. - Common Stock (RXRX) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 126M shares
.
Largest 10 shareholders include BAILLIE GIFFORD & CO (25.1M shares), VANGUARD GROUP INC (10.9M shares), BlackRock Inc. (10.6M shares), MIC Capital Management UK LLP (8.45M shares), Kinnevik AB (publ) (7.65M shares), STATE STREET CORP (6.37M shares), Data Collective IV GP, LLC (5.94M shares), Laurion Capital Management LP (4.83M shares), FMR LLC (4.76M shares), and NORGES BANK (4.23M shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.